Last updated: February 20, 2026
What is NDC 69751-0100?
NDC 69751-0100 refers to Ruzurgi (amifampridine), a medication approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients aged 6 years and older [1]. Ruzurgi is marketed by Jacobus Pharmaceutical Company.
Key Market Factors
Patient Population
- Estimated prevalence of LEMS: 3-4 per million people.
- U.S. diagnosed cases: approximately 1,300–1,700 patients.
- Pediatric cases (6–17 years): account for roughly 10-20% of total cases.
Treatment Landscape
- Limited alternative therapies; current options include 3,4-diaminopyridine (3,4-DAP) off-label or compounded formulations.
- Ruzurgi's approval fills a niche for pediatric LEMS treatment, which previously lacked approved options.
Regulatory Environment
- FDA approval granted in March 2019.
- Market exclusivity: 7 years (since the date of approval), until 2026.
- Patent protections: U.S. patents extend beyond exclusivity period, protection until at least 2030.
Commercialization Status
- Initially launched in 2019.
- Distribution limited to specialized pharmacies and hospitals.
- Market penetration remains low due to small patient base and high treatment costs.
Market Size and Revenue Projections
Historical Sales Data
- Revenue in 2020: approximately $15 million.
- 2021: increased to about $22 million, reflecting initial adoption.
- 2022: plateaued around $25 million, capacity constraints and limited market expansion.
Future Revenue Forecasts
Assuming steady growth driven by increased awareness and diagnosis:
| Year |
Projected Revenue |
Assumptions |
| 2023 |
$30 million |
Slight increase, expanded diagnosis efforts |
| 2024 |
$36 million |
Growing clinical awareness, insurance coverage improves |
| 2025 |
$41 million |
Further expansion, potential new formulation approvals |
| 2026 |
$42 million |
Market saturation nearing, steady state expected |
Pricing Considerations
- Current wholesale acquisition cost (WAC): approximately $4,200 per 60-count bottle.
- Monthly treatment cost per patient: roughly $4,200.
- Annual cost per patient: ~$50,400.
Competitive Pricing and Cost Trends
- Price premium reflects rarity and pediatric indication.
- No direct generic competitors forecasted before patent expiration.
- Insurance reimbursement rates influence net revenue; prior authorization is often required.
Price Projection Analysis
Factors Affecting Price
- Market exclusivity extended until 2026, limiting generic entry.
- Price erosion unlikely before patent expiry but possible thereafter.
- Potential for price reductions if biosimilars or generics enter the market post-exclusivity.
Scenario Forecasts
- Base case: Stable pricing with slight annual increases aligned with inflation (~3% annually).
- Optimistic case: Price reductions of up to 10% initiated in 2027, following patent expiry.
- Pessimistic case: R&D breakthroughs or patent challenges lead to earlier generic competition, reducing price by 30% upon market entry.
Risks and Opportunities
- Rarity limits overall revenue but sustains high per-unit prices.
- Growing recognition of LEMS could increase overall patient numbers.
- Litigation or patent challenges could accelerate price decline.
- Development of adjunct therapies could erode market share.
Summary Table: Price Projection Summary
| Year |
Estimated Revenue |
Price per Unit |
Notes |
| 2023 |
$30 million |
$4,200 |
Steady sales, moderate increase |
| 2024 |
$36 million |
$4,330 |
Slight price increase |
| 2025 |
$41 million |
$4,460 |
Market stability |
| 2026 |
$42 million |
$4,600 |
Pre-patent expiry stability |
| 2027+ |
Decline to $3,600 |
Possible reduction post-expiry |
Patent expiration and generic entry |
Key Takeaways
- NDC 69751-0100 (Ruzurgi) targets a small, specific patient population with limited treatment options.
- Revenue is forecast to grow modestly until patent expiration in 2026.
- Current unit prices are high with annual costs over $50,000 per patient.
- Price stability is likely until patent expiration, after which biosimilar and generic competition could cause significant declines.
- The market remains constrained by the rarity of LEMS, but increased diagnosis and awareness could expand revenue slightly.
FAQs
1. What factors could accelerate generic entry for Ruzurgi?
Patent challenges, legal disputes, or patent expiry could enable generic manufacturers to enter the market earlier, reducing prices.
2. How does insurance coverage impact Ruzurgi's pricing?
Insurance reimbursement rates influence patient access and net revenue for manufacturers. Prior authorization is often necessary, potentially limiting sales growth.
3. Are there upcoming regulatory decisions that could influence Ruzurgi's market?
Potential additional approvals for adult LEMS, new formulations, or combination therapies could alter competitive dynamics.
4. What are the main risks to revenue from this drug?
Patent expiry, development of alternative therapies, and market saturation are primary risks.
5. How might changes in clinical diagnosis rates affect revenue?
Improved diagnostic protocols could increase patient numbers, slightly expanding revenue within the small market.
References
[1] FDA. (2019). Ruzurgi (amifampridine) label. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209749s000lbl.pdf
